Company Overview
Company Type: Private Company
Website: densitashealth.com
Number of Employees: -
Year Founded: 2011
Total Amount Raised (CAD mm)†: 0.35
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Densitas Inc. develops breast imaging analytics software for radiology departments, DI departments, and healthcare systems. The company offers mammography solutions, which include densitas intelliMammo platform, comprising intelliMammo densityai, qualityai, and riskai. Densitas Inc. was incorporated in 2011 and is based in Halifax, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Abdolell, Mohamed 
Founder, CEO & Director
Bade, Alexandra 
Director of Global Sales & Operations

Key Board Members
Name
Title
Abdolell, Mohamed 
Founder, CEO & Director
Caines, Judy 
Member of Clinical Advisory Board
Kim, Jae K.
Director
Lee, Michael
Director
Sharma, Nisha 
Member of Clinical Advisory Board
Siegel, Eliot 
Member of Clinical Advisory Board
Spear, Georgia 
Member of Clinical Advisory Board


Primary Industry Classification
Health Care Technology


Primary Office Location
#66, 1344 Summer Street Suite 311B | Halifax, NS | B3H 0A8 | Canada
Phone: 902-405-4610   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Anges Québec
Jun-12-2019
Unknown
-
Growth
MEDTEQ, Le consortium de recherche et d'innovation en technologies médicales du Québec
Jun-12-2019
Minority
-
Growth
Real Investment Management Inc.
Jun-12-2019
Unknown
-
Growth
Invest Nova Scotia
Oct-11-2012
Unknown
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-12-2019
Jun-12-2019
Private Placement
Target
Densitas Inc.
Invest Nova Scotia,Anges Québec,Real Investment Management Inc.,MEDTEQ, Le consortium de recherche et d'innovation en technologies médicales du Québec Buyer Funds:Anges Québec Capital Fund

-
Nov-25-2015
Nov-25-2015
Private Placement
Target
Densitas Inc.


0.11
Oct-21-2015
Oct-21-2015
Private Placement
Target
Densitas Inc.
Invest Nova Scotia

-
Oct-11-2012
Oct-11-2012
Private Placement
Target
Densitas Inc.
Invest Nova Scotia

0.15
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Nov-29-2022
Client Announcements
Desert Imaging Deploys Densitas® IntelliMammo™ A.I. Solutions for Breast Screening Services
Nov-28-2022
Client Announcements
Densitas Inc Connects to Nuance Precision Imaging Network to Empower Collaborative Care Teams and Improve Patient Outcomes with Workflow-Integrated Ai
May-12-2022
Client Announcements
Densitas® and Blackford Expand Partnership to Offer Breast Cancer Risk and Image Quality Solutions
Nov-29-2021
Executive/Board Changes - Other
Densitas® Names Alexandra Bade as New Director, Global Sales and Operations to Lead Market Expansion
Oct-28-2021
Client Announcements
Densitas® Deploys intelliMammo™ A.I. Platform in Partnership with RAD-AID International for Breast Screening Quality Assurance and Technologist Training in Guyana

Competitors
Hologic, Inc. (NasdaqGS:HOLX), iCAD, Inc. (NasdaqCM:ICAD), Lunit Inc. (KOSDAQ:A328130), Screenpoint Medical B.V., Therapixel SA, Volpara Solutions Inc.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Abdolell, Mohamed 
Founder, CEO & Director
902-405-4610
-
mo@densitas.ca
Caines, Judy 
Member of Clinical Advisory Board
902-405-4610
-
-
Kim, Jae K.
Director
902-405-4610
-
-
Lee, Michael
Director
902-405-4610
-
Mike.lee@rci.rogers.com
Sharma, Nisha 
Member of Clinical Advisory Board
902-405-4610
-
-
Siegel, Eliot 
Member of Clinical Advisory Board
902-405-4610
-

Spear, Georgia 
Member of Clinical Advisory Board
902-405-4610
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Abdolell, Mohamed 
Founder, CEO & Director
902-405-4610
-
mo@densitas.ca
Bade, Alexandra 
Director of Global Sales & Operations
902-405-4610
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
